Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties.

Animals Carcinogenesis / genetics Cell Line, Tumor Cell Survival Clone Cells Cluster Analysis Female Gain of Function Mutation Humans Inflammation / pathology Intestinal Neoplasms / pathology Liver Neoplasms / secondary Loss of Heterozygosity MAP Kinase Signaling System Mice Mutation / genetics Organoids / pathology Tumor Suppressor Protein p53 / genetics

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
11 05 2020
Historique:
received: 03 08 2019
accepted: 23 04 2020
entrez: 13 5 2020
pubmed: 13 5 2020
medline: 6 8 2020
Statut: epublish

Résumé

Missense-type mutant p53 plays a tumor-promoting role through gain-of-function (GOF) mechanism. In addition, the loss of wild-type TP53 through loss of heterozygosity (LOH) is widely found in cancer cells. However, malignant progression induced by cooperation of TP53 GOF mutation and LOH remains poorly understood. Here, we show that mouse intestinal tumors carrying Trp53 GOF mutation with LOH (AKTP

Identifiants

DOI: 10.1038/s41467-020-16245-1 PMID: 32393735 PMC: PMC7214469
pubmed: 32393735
doi: 10.1038/s41467-020-16245-1
pii: 10.1038/s41467-020-16245-1
pmc: PMC7214469
doi:

Substances chimiques

Tumor Suppressor Protein p53 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2333

Références

Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer 49, 1374–1403 (2013).
pubmed: 23485231 doi: 10.1016/j.ejca.2012.12.027
Siegel, R. L. et al. Colorectal cancer statistics, 2017. CA Cancer J. Clin. 67, 177–193 (2017).
pubmed: 28248415 doi: 10.3322/caac.21395
Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).
pubmed: 24132290 pmcid: 3927368 doi: 10.1038/nature12634
The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).
pmcid: 3401966 doi: 10.1038/nature11252 pubmed: 3401966
Giannakis, M. et al. Genome correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 15, 857–865 (2016).
pubmed: 27149842 pmcid: 4850357 doi: 10.1016/j.celrep.2016.03.075
Baker, S. J. et al. p53 gene mutation occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 50, 7717–7722 (1990).
pubmed: 2253215
Brannon, A. R. et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol. 15, 454 (2014).
pubmed: 25164765 pmcid: 4189196 doi: 10.1186/s13059-014-0454-7
Brosh, R. & Rotter, V. When mutations gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 9, 701–713 (2009).
pubmed: 19693097 doi: 10.1038/nrc2693
Muller, P. A. J. & Vousden, K. H. Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell 25, 304–317 (2014).
pubmed: 24651012 pmcid: 3970583 doi: 10.1016/j.ccr.2014.01.021
Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847–860 (2004).
pubmed: 15607980 doi: 10.1016/j.cell.2004.11.004
Lang, G. A. et al. Gain of function of a p53 hot spot mutatino in a mouse model of Li-Fraumeni syndrome. Cell 119, 861–872 (2004).
pubmed: 15607981 doi: 10.1016/j.cell.2004.11.006
Morton, J. P. et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc. Natl Acad. Sci. USA 107, 246–251 (2010).
pubmed: 20018721 doi: 10.1073/pnas.0908428107
Nakayama, M. et al. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular structure. Oncogene 36, 5885–5896 (2017).
pubmed: 28628120 pmcid: 5658682 doi: 10.1038/onc.2017.194
Nakayama, M. & Oshima, M. Mutant p53 in colon cancer. J. Mol. Cell Biol. 11, 267–276 (2019).
pubmed: 30496442 doi: 10.1093/jmcb/mjy075
Alexandrova, E. M. et al. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature 523, 352–356 (2015).
pubmed: 26009011 pmcid: 4506213 doi: 10.1038/nature14430
Lu, X., Liu, D. P. & Xu, Y. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis. Oncogene 32, 2900–2906 (2013).
pubmed: 22824795 doi: 10.1038/onc.2012.299
Solomon, H. et al. Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers. Oncogene 37, 1669–1684 (2018).
pubmed: 29343849 pmcid: 6448595 doi: 10.1038/s41388-017-0060-8
Koifman, G. et al. A Mutant p53-dependent embryonic stem cell gene signature is associated with augmented tumorigenesis of stem cells. Cancer Res. 78, 5833–5847 (2018).
pubmed: 30154152
Muller, P. A. J. et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 139, 1327–1341 (2009).
pubmed: 20064378 doi: 10.1016/j.cell.2009.11.026 pmcid: 20064378
Adomo, M. et al. A mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis. Cell 137, 87–98 (2009).
doi: 10.1016/j.cell.2009.01.039
Weissmueller, S. et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell 157, 382–394 (2014).
pubmed: 24725405 pmcid: 4001090 doi: 10.1016/j.cell.2014.01.066
Zhu, J. et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 525, 206–211 (2015).
pubmed: 26331536 pmcid: 4568559 doi: 10.1038/nature15251
Pfister, N. T. et al. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Gene Dev. 29, 1298–1315 (2015).
pubmed: 26080815 doi: 10.1101/gad.263202.115 pmcid: 26080815
Parikh, N. et al. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J. Pathol. 232, 522–533 (2014).
pubmed: 24374933 pmcid: 4362779 doi: 10.1002/path.4321
Alexandrova, E. M. et al. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo. Cell Death Differ. 8, e2661 (2017).
doi: 10.1038/cddis.2017.80
Sakai, E. et al. Combined mutation of Apc, Kras, and Tgfbr2 effectively drives metastasis of intestinal cancer. Cancer Res. 78, 1334–1346 (2018).
pubmed: 29282223 doi: 10.1158/0008-5472.CAN-17-3303
Markowitz, S. D. & Bertagnolli, M. M. Molecular basis of colorectal cancer. New Eng. J. Med. 361, 2449–2460 (2009).
pubmed: 20018966 doi: 10.1056/NEJMra0804588
Lambert, A. W., Pattabiraman, D. R. & Weinberg, R. A. Emerging biological principles of metastasis. Cell 168, 670–691 (2017).
pubmed: 28187288 pmcid: 5308465 doi: 10.1016/j.cell.2016.11.037
Hofmann, C. et al. Cell-cell contacts prevent anoikis in primary human colonic epithelial cells. Gastroenterology 132, 587–600 (2007).
pubmed: 17258732 doi: 10.1053/j.gastro.2006.11.017
Vousden, K. H. & Lu, X. Live or let die: The cell’s response to p53. Nat. Rev. Cancer 2, 594–604 (2002).
pubmed: 12154352 doi: 10.1038/nrc864
Uchi, R. et al. Integrated multiregional analysis proposing a new model of colorectal cancer evolution. PLoS Genet 12, e1005778 (2016).
pubmed: 26890883 pmcid: 4758664 doi: 10.1371/journal.pgen.1005778
Shetzer, Y. et al. The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele. Cell Death Differ. 21, 1419–1431 (2014).
pubmed: 24832469 pmcid: 4131174 doi: 10.1038/cdd.2014.57
Tang, J. et al. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis. Lab Invest 99, 1454–1469 (2019).
pubmed: 31148594 pmcid: 6759392 doi: 10.1038/s41374-019-0269-y
Schulz-Heddergott, R. et al. Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion. Cancer Cell 34, 298–314 (2018).
pubmed: 30107178 pmcid: 6582949 doi: 10.1016/j.ccell.2018.07.004
Dienstmann, R. et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer 17, 79–92 (2017).
pubmed: 28050011 doi: 10.1038/nrc.2016.126
Takeishi, S. & Nakayama, K. I. Role of Fbxw7 in the maintenance of normal stem cells and cancer-initiating cells. Br. J. Cancer 111, 1054–1059 (2014).
pubmed: 24853181 pmcid: 4453837 doi: 10.1038/bjc.2014.259
Kim, H. S. et al. Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc. Cancer Res 72, 6065–6075 (2012).
pubmed: 22986743 doi: 10.1158/0008-5472.CAN-12-2594
Andrews, S. FastQC. A quality control tool for high throughput sequence data. http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (2010).
Parekh, S., Ziegenhain, C., Vieth, B., Enard, W. & Hellman, I. The impact of amplification on differential expression analyses by RNA-seq. Sci. Rep. 6, 25533 (2016).
pubmed: 27156886 pmcid: 4860583 doi: 10.1038/srep25533
Palomares, M. A. et al. Systematic analysis of TruSeq, SMARTer and SMARTer Ultra-Low RNA-seq kits for standard, low and ultra-low quantity samples. Sci. Rep. 9, 7550 (2019).
pubmed: 31101892 pmcid: 6525156 doi: 10.1038/s41598-019-43983-0
Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562–578 (2012).
pubmed: 22383036 pmcid: 22383036 doi: 10.1038/nprot.2012.016
Kim, D. et al. TopHat2: accurate of transcriptomes in the presence of insertions, deletions and gene fusions. Genom. Biol. 14, R36 (2013).
doi: 10.1186/gb-2013-14-4-r36
Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcription and isoform switching during cell differentiation. Nat. Biotech. 28, 511–515 (2010).
doi: 10.1038/nbt.1621
Wang, L., Wang, S. & Li, W. RSeQC: quality control of RNA-seq experiments. Bioinformatics 28, 2184–2185 (2012).
pubmed: 22743226 doi: 10.1093/bioinformatics/bts356 pmcid: 22743226
Pinto, J. P. et al. StemChecker: a web-based tool to discover and explore stemness signatures in gene sets. Nucleic Acids Res. 43, W72–W77 (2015).
pubmed: 26007653 pmcid: 4489266 doi: 10.1093/nar/gkv529
Jensen, L. J. et al. STRING 8–a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 37, D412–D416 (2009).
pubmed: 18940858 doi: 10.1093/nar/gkn760 pmcid: 18940858

Auteurs

Mizuho Nakayama (M)

Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, 920-1192, Japan.
WPI Nano Life Science Institute, Kanazawa University, Kanazawa, 920-1192, Japan.

Chang Pyo Hong (CP)

Theragen Etex Bio Institute, Suwon, 16229, Republic of Korea.

Hiroko Oshima (H)

Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, 920-1192, Japan.
WPI Nano Life Science Institute, Kanazawa University, Kanazawa, 920-1192, Japan.

Eri Sakai (E)

Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, 920-1192, Japan.

Seong-Jin Kim (SJ)

Theragen Etex Bio Institute, Suwon, 16229, Republic of Korea.
Precision Medicine Research Center, Advanced Institute of Convergence Technology and Department of Transdisciplinary Studies, Seoul National University, Suwon, 16229, Republic of Korea.

Masanobu Oshima (M)

Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, 920-1192, Japan. oshimam@staff.kanazawa-u.ac.jp.
WPI Nano Life Science Institute, Kanazawa University, Kanazawa, 920-1192, Japan. oshimam@staff.kanazawa-u.ac.jp.
ORCID: 0000-0002-3304-0004

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Carcinogenèse › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Survie cellulaire › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › Cellules › Cellules cultivées › Clones cellulaires › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de regroupements › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Mutation gain de fonction › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Tumeurs de l'intestin › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Déséquilibre allélique › Perte d'hétérozygotie › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Système de signalisation des MAP kinases › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › Tissus › Organoïdes › Loss of wild-type p53 promotes mutant...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › Loss of wild-type p53 promotes mutant...